LCK and acute lymphoblastic leukemia: Lymphocyte cell–specific protein-tyrosine kinase (LCK) activity is required for proliferation and survival of T-ALL, and recently, it was demonstrated that a big proportion of pediatric and adult T-ALL cases respond to dasatinib, a well-known LCK inhibitor (25, 26).